|
|
.
NPI Detail
NPI: 1467420448
Type: Organization
Taxonomy Code: 282N00000X
Hospital-General
Hospitals/General Acute Care Hospital
3950 XXXXXXX XX
AUSTELL, GA 301061121
Business phone: (XXX) XXX-XXXX
Mailing address phone: (XXX) XXX-XXXX
|
Click here for new NPI search.
|
2021 OPPS Part A Medicare Services Submitted NPI-1467420448*
OPPS Payment Method "A" - Services not paid under OPPS; uses a different fee schedule (e.g., ambulance, PT, mammography)
Top Level I HCPC Procedures
| Procedure | Description | Number Submitted | Medicare Payment |
| 36415
|
ROUTINE VENIPUNCTURE
|
XXXXX
|
$XXXXX.XX
|
| 85025
|
COMPLETE CBC W/AUTO DIFF WBC
|
XXXXX
|
$XXXXXX.XX
|
| 80053
|
COMPREHEN METABOLIC PANEL
|
XXXXX
|
$XXXXXX.XX
|
Top Drugs Administered Other than Oral Method
| Procedure | Description | Number Submitted | Medicare Payment |
| J1439
|
Inj ferric carboxymaltos 1mg
|
XXXXXX
|
$XXXXXX.XX
|
| J9271
|
Inj pembrolizumab
|
XXXXXX
|
$XXXXXXX.XX
|
| J1642
|
Inj heparin sodium per 10 u
|
XXXXXX
|
-
|
| J0881
|
Darbepoetin alfa, non-esrd
|
XXXXXX
|
$XXXXXX.XX
|
| J9025
|
Azacitidine injection
|
XXXXXX
|
$XXXXX.XX
|
| J9299
|
Injection, nivolumab
|
XXXXXX
|
$XXXXXXX.XX
|
| J0878
|
Daptomycin injection
|
XXXXXX
|
-
|
| J0897
|
Denosumab injection
|
XXXXXX
|
$XXXXXXX.XX
|
| J9263
|
Oxaliplatin
|
XXXXXX
|
-
|
| J1442
|
Inj filgrastim excl biosimil
|
XXXXX
|
$XXXXX.XX
|
| J9306
|
Injection, pertuzumab, 1 mg
|
XXXXX
|
$XXXXXX.XX
|
| J9267
|
Paclitaxel injection
|
XXXXX
|
-
|
| J0131
|
Inj, acetaminophen (nos)
|
XXXXX
|
-
|
| J0185
|
Inj., aprepitant, 1 mg
|
XXXXX
|
$XXXXX.XX
|
| J9264
|
Paclitaxel protein bound
|
XXXXX
|
$XXXXXX.XX
|
| J9144
|
Daratumumab, hyaluronidase
|
XXXXX
|
$XXXXXXX.XX
|
| J2704
|
Inj, propofol, 10 mg
|
XXXXX
|
-
|
| J1459
|
Inj ivig privigen 500 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J1100
|
Dexamethasone sodium phos
|
XXXXX
|
-
|
| J9176
|
Injection, elotuzumab, 1mg
|
XXXXX
|
$XXXXXX.XX
|
| J9171
|
Docetaxel injection
|
XXXXX
|
-
|
| J9035
|
Bevacizumab injection
|
XXXXX
|
$XXXXXXX.XX
|
| J9312
|
Inj., rituximab, 10 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J0256
|
Alpha 1 proteinase inhibitor
|
XXXXX
|
$XXXXX.XX
|
| J9022
|
Inj, atezolizumab,10 mg
|
XXXXX
|
$XXXXXXX.XX
|
| J9355
|
Inj trastuzumab excl biosimi
|
XXXXX
|
$XXXXXXX.XX
|
| J3262
|
Tocilizumab injection
|
XXXXX
|
$XXXXX.XX
|
| J9358
|
Inj fam-trastu deru-nxki 1mg
|
XXXXX
|
$XXXXXX.XX
|
| J9034
|
Inj., bendeka 1 mg
|
XXXXX
|
$XXXXXX.XX
|
| J1930
|
Lanreotide injection
|
XXXXX
|
$XXXXXX.XX
|
| J2795
|
Ropivacaine hcl injection
|
XXXXX
|
-
|
| J1453
|
Fosaprepitant injection
|
XXXXX
|
$XXXX.XX
|
| J0485
|
Belatacept injection
|
XXXXX
|
$XXXXX.XX
|
| J9173
|
Inj., durvalumab, 10 mg
|
XXXXX
|
$XXXXXXX.XX
|
Top HCPC Level II Procedures / Professional Services
| Procedure | Description | Number Submitted | Medicare Payment |
* Medicare Part A utilization data is derived from the 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
|
